Sources of common compounds:

Electric Literature of 1003-21-0,Some common heterocyclic compound, 1003-21-0, name is 5-Bromo-1-methyl-1H-imidazole, molecular formula is C4H5BrN2, traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route.

Method 10; A mixture of 4-(4-chloro-phenyl)-4-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl]-piperidine-l-carboxylic acid tert-butyl ester (200 mg, 0.4 mmol), bis(tri-t- butylphosphine)palladium (0) (6 mg, 3 mol%), 5-bromo-l-methylimidazole (84 mg, 0.5 mmol), potassium carbonate (299 mg, 1.4 mmol), ethanol (1.1 ml), toluene (1.1 ml) methanol (1.6 ml) and water (1.5 ml) was heated in a CEM Explorer microwave to 80 0C for 30 minutes using < 50 watts power. The solvents were removed and the residue was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with brine, dried (MgSO4) and concentrated under reduced pressure. The crude reaction mixture was purified by SCX ion exchange column chromatography eluting with an ammonia-dichloromethane-methanol EPO mixture to furnish the protected amine. The protecting group was removed by stirring at room temperature in dichloromethane (1 ml) and trifluoroacetic acid (1 ml) for 30 minutes before concentrating and re-concentrating from methanol (x3). The residue was purified by silica column chromatography eluting with a gradient from DMAW90 to DMAW60 furnishing the desired compound in ~90% purity.

The synthetic route of 1003-21-0 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; ASTEX THERAPEUTICS LIMITED; THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL; CANCER RESEARCH TECHNOLOGY LIMITED; WO2006/136823; (2006); A1;,
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem